Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP (COVID-19)
2015-002340-14Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydrocortisone, dexamethasone, ivermectin, imatinib, oseltamivir and 21 more in community-acquired pneumonia (CAP) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: All-cause mortality at 90 days. Started Jul 2015; status: active.
02
Drugs
03
Conditions
community-acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2015-002340-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002340-14.